Healthcare buyers used to focus on products, clinics, software seats, and market share. In 2026, many deals turn on something harder to see: proprietary health data.
That shift matters because unique data can raise valuation, speed expansion, and give a buyer an edge that rivals can’t easily copy. A company may look like a rehab platform or remote monitoring app on the surface. Underneath, it may hold years of patient outcomes, care-path data, and workflow signals that make AI tools smarter and care decisions better.
The pattern is showing up across digital health, provider tech, rehab, remote monitoring, and biopharma. In plain terms, data has moved from side asset to deal currency.
What makes proprietary health data so valuable in M&A
Proprietary health data is information a company has collected, organized, and can lawfully use in ways others can’t easily match. That can include patient outcomes, imaging libraries, claims patterns, remote monitoring signals, clinical workflow data, and real-world evidence tied to treatment response.
Its value comes from five traits. First, it’s exclusive. Second, it has scale. Third, the data quality is high enough to trust. Fourth, it has depth over time, so trends show up, not just snapshots. Fifth, teams can actually use it inside products, models, and decision tools.
When those traits come together, data stops being a storage problem and starts acting like a business moat. That’s why more buyers look beyond revenue multiples and ask what sits inside the target’s data layer. A broader view of that shift appears in this 2026 analysis of health system data monetization.
Not all health data is equal, buyers pay more for data they can actually use
A giant pile of records isn’t the same as a strong data asset. Raw files can be incomplete, mislabeled, or trapped in old systems. That lowers value fast.
Buyers pay more for data that is cleaned, normalized, permissioned, and mapped to real outcomes. For example, blood pressure readings mean more when they connect to medication changes, adherence, and later results. A million messy records may look impressive. Ten thousand well-structured longitudinal records can be more useful.
Data gets more valuable when it improves AI, automation, and patient results
The best datasets do more than sit in a warehouse. They improve triage tools, help predict risk, support personalized care, and automate workflows that burn staff time.
That link to action is what raises the price. If a buyer can use the target’s data to train models, improve product performance, and prove ROI to customers, the asset supports growth in several directions at once. In other words, the data isn’t just content. It’s fuel.
Why buyers are using health data as a deal lever in 2026
Several forces are pushing this trend at the same time. AI demand is the loudest one, but it’s not the only driver. Health records are still fragmented. Providers want better care coordination. Payers and employers want proof that programs improve outcomes. Drug makers want real-world evidence that helps with development and commercialization.
At the same time, digital health firms face pressure to show durable results, not just engagement. That pushes buyers toward assets that can back claims with evidence. According to CB Insights’ 2026 digital health predictions, AI, automation, and outcome pressure are now shaping where capital goes across healthcare.
AI has made hard-to-copy data sets more strategic than ever
Generic public data isn’t enough for many healthcare AI tools. It often lacks context, longitudinal depth, or clean outcome labels. Buyers want assets that help models perform in real clinical settings, not just in demos.
That is why medical record unification, structured extraction, and AI-ready datasets draw so much attention. A company that can combine records across systems and turn them into usable inputs becomes far more attractive than one with a flashy interface but weak underlying data.
Buyers want faster growth, and data-rich assets can shorten the path
Acquiring trusted data can speed market entry. It can also strengthen an existing product without years of internal collection work.
A rehab platform with strong outcome data can help a buyer win provider contracts faster. A remote monitoring company with validated patient signals can improve care measurement right away. A specialty platform with years of treatment-response data can open a new research or pharma channel. Time matters in M&A, and data-rich assets often buy time.
Recent deals show how data is shaping healthcare valuations
Early 2026 offers clear examples. Many of the most interesting deals added data infrastructure, outcomes data, or real-world evidence, not just customers.
This snapshot shows the pattern:
| Deal | Data asset added | Why it mattered |
|---|---|---|
| Harmony Healthcare IT acquired Blue Elm | EHR extraction, migration, and legacy system data access across 500+ hospitals | Gave the buyer stronger pipes for pulling usable records from older systems |
| Net Health acquired Keet Health | Outcomes tracking and remote monitoring data for rehab | Expanded measurable patient progress data inside rehab workflows |
| Sword Health acquired Kaia Health | Digital therapy and home-based musculoskeletal engagement data | Added more treatment and monitoring signals for care at home |
| Verana Health merged with COTA | Multi-specialty real-world data, especially in oncology | Increased scale and depth for research and commercial use |
The takeaway is simple: the buyer often wants the data engine under the brand. That’s why this 2026 health tech M&A overview keeps pointing back to AI readiness, interoperability, and post-close usability.
Some deals are really bets on better data infrastructure, not just bigger market share
Blue Elm is a good example. On paper, data extraction and migration may sound less exciting than a patient-facing app. In practice, those capabilities matter because they help buyers collect, clean, move, and activate records from messy environments.
That infrastructure can become the difference between having data and being able to use it. Buyers know that. So they often pay for the pipes, not just the endpoints.
In biotech and pharma, real-world evidence can raise the strategic value of a target
Biopharma deals follow the same logic. Data tied to treatment response, patient mix, and post-market outcomes can reduce risk and sharpen strategy. It helps with trial planning, label expansion, physician targeting, and safety monitoring.
The Verana Health and COTA combination shows how real-world data itself can be part of the strategic prize. In these cases, milestone-based structures can also help buyers manage uncertainty if future data performance affects value.
The biggest risks buyers must check before treating data like currency
Data only works like currency if it stays legal, trusted, and useful after close.
Data is only worth what a buyer can actually use, keep, and defend.
That means diligence has to go deeper than record counts. Buyers need to test privacy controls, consent terms, interoperability, cyber risk, reimbursement exposure, and governance. If those pieces are weak, the headline story can fall apart.
Bad data quality can weaken a deal even when the story sounds strong
A target may claim it has rich longitudinal records. Yet the buyer may find missing fields, weak labeling, duplicate patients, or poor documentation. That changes the asset’s real value.
Poor quality also raises integration costs. Teams spend months cleaning files, remapping fields, and fixing broken workflows. As a result, expected synergies show up late or not at all.
Privacy, compliance, and ethics can quickly change what the data is worth
Lawful access matters just as much as technical quality. Buyers need to verify patient permissions, data-use rights, de-identification practices, vendor agreements, and AI governance rules.
The compliance bar remains high in 2026, and these health care privacy law takeaways show why privacy programs can no longer be an afterthought in deal work. A data asset that looks powerful in a teaser may become limited after a hard legal review. Ethics matter too, especially when sensitive health data feeds AI tools.
What this trend means for founders, investors, and healthcare operators
For founders, the message is clear. Don’t just collect data. Make it useful, lawful, and outcome-linked. Document permissions. Improve governance. Build systems that can share data across teams and partners.
For investors, diligence should focus on evidence, not volume. Ask whether the dataset improves retention, care quality, or product performance. Ask whether it travels well after an acquisition. Also ask whether the company can prove the data supports pricing power or expansion.
For operators, this trend changes where value gets built. Clean workflows, strong documentation, and interoperable systems now affect enterprise value. In 2026, the winners aren’t the firms with the most data. They’re the ones that can show the clearest proof that their data works.
When that proof exists, proprietary health data becomes more than an internal asset. It becomes a real negotiating chip at the deal table.
Proprietary health data is becoming M&A currency because it can shape valuation, speed strategy, and strengthen AI, care delivery, and research. The next wave of healthcare deals will reward companies that can prove their data is unique, compliant, tied to outcomes, and easy to use after the close. In a crowded market, that’s what turns information into an asset buyers will pay up for.
